IVERIC bio, Inc. (ISEE)
| Market Cap | 547.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.59M |
| Shares Out | 92.68M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $6.14 |
| Previous Close | $6.01 |
| Change ($) | 0.13 |
| Change (%) | 2.16% |
| Day's Open | 6.02 |
| Day's Range | 5.76 - 6.20 |
| Day's Volume | 463,602 |
| 52-Week Range | 2.64 - 7.98 |
NEW YORK--(BUSINESS WIRE)--IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.
NEW YORK--(BUSINESS WIRE)--IVERIC bio granted a newly hired employee a non-statutory stock option to purchase 34,000 shares of the Company's common stock.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced today that the Company will participate in upcoming virtual investor conferences in November.
Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund ta...
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020.
IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.
NEW YORK--(BUSINESS WIRE)--IVERIC bio granted two newly hired, non-executive employees a non-statutory stock option to purchase 34,000 shares of the Company’s common stock.
NEW YORK--(BUSINESS WIRE)--IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2020 Results - Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced Pravin Dugel, MD will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Aug. 12, 2020.
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced the election of Mark S. Blumenkranz, M.D.
IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News
An upsized public offering has investors increasingly confident about its prospects.
Shares of New York-based biopharma IVERIC bio Inc (NASDAQ: ISEE) were advancing strongly Monday morning on the back of a positive clinical readout.
NEW YORK, June 15, 2020 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive 18 month results from the Company's first Phase 3 clinical trial (OPH2003) for Zimura® (avacinc...
IVERIC bio (ISEE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 13th
Top Ranked Momentum Stocks to Buy for May 12th
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2020 Results - Earnings Call Transcript
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2019 Results - Earnings Call Transcript
After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...
Iveric Bio Inc’s (NASDAQ: ISEE) lead asset, Zimura, could begin a pivotal clinical study in the geographic atrophy market in the quarter, according to Wedbush.
Although talking about stocks to sell typically elicits anger and negative emotions, this list is all about protecting your interests.
Seven biotechs led the way.
IVERIC bio: Promising Data In GA, Valuation Still Cheap With Multiple Catalysts In 2020
IVERIC bio (ISEE) reported earnings 30 days ago. What's next for the stock?
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2019 Results - Earnings Call Transcript
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2019 Results - Earnings Call Transcript
Market indexes soared Wednesday as investors anticipate an interest rate cut ahead.
About ISEE
IVERIC bio, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement w... [Read more...]
| Industry Biotechnology | Founded 2007 |
| CEO David Guyer | Employees 55 |
| Stock Exchange NASDAQ | Ticker Symbol ISEE |
Analyst Forecasts
According to 3 analysts, the average rating for IVERIC bio stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 111.73% from the latest price.